Q-omics provides the consensus-scored EPHA8 profile across patient tissues and cancer cell-line models. EPHA8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPHA8 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, EPHA8 RNA expression shows 11,966 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where EPHA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHA8 survival associations across molecular data types. EPHA8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHA8 RNA expression–survival associations across cancer types. High EPHA8 expression shows unfavorable associations in KIRC, UVM, LIHC, SKCM, THYM and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPHA8 RNA expression.
This table summarizes EPHA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EPHA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHA8 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, LUSC, UCEC and COAD. The HNSC box plot shows higher EPHA8 RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p = .001).
This table shows molecular features associated with EPHA8 in patient tissues and cancer cell lines. In patient samples, EPHA8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
